Free tool
Drug Search
Every brand-name drug and biologic application (NDA or BLA) in Drugs@FDA: 5,899 in all. Generic (ANDA) applications are not listed; their reference drug is.
Last checked: Nov 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
9 matches for "Celltrion INC"
Brand names that start with your search come first, then marketed and novel drugs.
| Drug | Sponsor | Application | First approved | Programs |
|---|---|---|---|---|
| Avtozma Tocilizumab-Anoh | Celltrion INC | BLA761498 | Jan 21, 2026 | |
| Avtozma Tocilizumab-Anoh | Celltrion INC | BLA761420 | Jan 24, 2025 | |
| Truxima Rituximab-Abbs | Celltrion INC | BLA761088 | Nov 28, 2018 | |
| Omlyclo Omalizumab-Igec | Celltrion INC | BLA761399 | Mar 7, 2025 | |
| Herzuma Trastuzumab-Pkrb | Celltrion INC | BLA761091 | Dec 14, 2018 | |
| Steqeyma Ustekinumab-Stba | Celltrion, Inc. | BLA761338 | Dec 17, 2024 | |
| Osenvelt Denosumab-Bmwo | Celltrion INC | BLA761404 | Feb 28, 2025 | |
| Eydenzelt Aflibercept-Boav | Celltrion INC | BLA761377 | Oct 2, 2025 | |
| Inflectra Infliximab-Dyyb | Celltrion INC | BLA125544 | Apr 5, 2016 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.